Wedbush Issues Positive Outlook for Replimune Group Earnings

Key Points

• Wedbush analysts have raised their FY2027 earnings estimate for Replimune Group to ($1.51) per share, improving from a prior estimate of ($2.24), with an "Outperform" rating and a price target of $18.00.
• The company's recent quarterly earnings report showed a loss of ($0.95) EPS, missing the consensus estimate by ($0.12).
• Several analysts have recently downgraded Replimune Group's stock, with price targets dropped significantly, reflecting mixed sentiment among analysts regarding its future performance.

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Investment analysts at Wedbush raised their FY2027 earnings estimates for Replimune Group in a research note issued on Monday, October 20th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($1.51) per share for the year, up from their previous estimate of ($2.24). Wedbush has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for Replimune Group's current full-year earnings is ($2.97) per share. Wedbush also issued estimates for Replimune Group's FY2028 earnings at ($0.68) EPS, FY2029 earnings at ($0.03) EPS and FY2030 earnings at $0.44 EPS.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12).

Several other equities analysts have also recently commented on the stock. Jefferies Financial Group reduced their price objective on shares of Replimune Group from $31.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Barclays cut shares of Replimune Group from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $17.00 to $3.00 in a research note on Wednesday, July 23rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Replimune Group in a research note on Tuesday, October 14th. Leerink Partnrs raised shares of Replimune Group from a "hold" rating to a "strong-buy" rating in a research note on Monday. Finally, BMO Capital Markets cut shares of Replimune Group from an "outperform" rating to an "underperform" rating and cut their price target for the stock from $27.00 to $2.00 in a research note on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, Replimune Group presently has a consensus rating of "Hold" and an average target price of $11.00.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $8.10 on Wednesday. The company has a 50 day moving average of $5.17 and a 200 day moving average of $7.29. The stock has a market cap of $632.25 million, a P/E ratio of -2.50 and a beta of 0.42. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The company has a current ratio of 6.94, a quick ratio of 6.94 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in REPL. Moody Aldrich Partners LLC purchased a new stake in shares of Replimune Group in the 1st quarter valued at $1,925,000. Bank of New York Mellon Corp boosted its stake in shares of Replimune Group by 8.4% in the 1st quarter. Bank of New York Mellon Corp now owns 189,177 shares of the company's stock valued at $1,844,000 after purchasing an additional 14,659 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Replimune Group by 19.7% in the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock valued at $151,000 after purchasing an additional 2,545 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Replimune Group by 67.4% in the 1st quarter. Victory Capital Management Inc. now owns 75,140 shares of the company's stock valued at $733,000 after purchasing an additional 30,260 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Replimune Group by 106.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company's stock valued at $111,000 after purchasing an additional 5,876 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Insider Activity

In other news, CFO Emily Luisa Hill sold 9,154 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the sale, the chief financial officer owned 134,368 shares of the company's stock, valued at approximately $721,556.16. This represents a 6.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.20% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.